Lecirelin Injection

Acromegaly is a chronic disease caused by excessive secretion of growth hormone (GH) from the anterior pituitary gland. Continuous excessive GH can stimulate the liver to produce insulin-like growth factor-1 (IGF-1), leading to abnormal proliferation of bones and soft tissues. Patients often present with enlarged hands and feet, thicker and longer fingers and toes; Facial changes, such as protruding eyebrows and jaw, thickening of nose and lips; Joint pain and limited mobility; Visceral hypertrophy can lead to serious complications such as cardiac hypertrophy and respiratory dysfunction. As a somatostatin analogue, it can precisely activate the somatostatin receptor (SSTR2/SSTR5) on the surface of pituitary GH cells. Through this mechanism of action, the secretion of GH is effectively inhibited, reducing the generation of IGF-1 at the root.

With the decrease of GH levels, abnormal proliferation of soft tissues is controlled, the volume gradually shrinks, joint stiffness symptoms are relieved, and metabolic abnormalities are significantly improved. Clinical data shows that after standardized treatment, 70% -80% of patients' GH levels can be reduced to the normal range. Moreover, long-term use of this drug can continuously inhibit excessive secretion of GH, delay disease progression, and reduce the risk of complications. Usually used for patients with residual lesions or disease recurrence after surgery, it can also be used as a transitional treatment during the waiting period for radiotherapy to buy time for subsequent treatment.

In hormone dependent prostate cancer, the growth and proliferation of tumor cells depend on the stimulation of androgens (mainly testosterone). As a gonadotropin-releasing hormone (GnRH) analogue, it has unique pharmacological effects. It continuously stimulates the pituitary GnRH receptor, causing desensitization of the receptor and subsequently inhibiting the secretion of gonadotropins (FSH/LH). Due to the crucial regulatory role of FSH and LH in the production of testosterone in the testes, a decrease in their secretion can lead to a significant decrease in testosterone levels, ultimately resulting in castration. The decrease in testosterone levels can effectively slow down the proliferation rate of prostate cancer cells, inhibit tumor growth and spread, and thus prolong the survival of patients.

Research has shown that after treatment, patients' prostate-specific antigen (PSA) levels can decrease by more than 50%. PSA is an important tumor marker for prostate cancer, and the decrease in its level reflects the remission of the tumor. In addition, the combination with chemotherapy can exert a synergistic effect, further enhancing the killing effect on tumor cells and improving clinical efficacy. This drug is suitable for patients with locally advanced or metastatic prostate cancer, especially for those who are intolerant to surgical castration or require long-term hormone therapy, making it an ideal treatment option.

There are estrogen receptors (ER) and/or progesterone receptors (PR) on the surface of hormone receptor positive breast cancer tumor cells, and their growth and proliferation are regulated by estrogen. Exerting anti-tumor effects through multiple pathways. On the one hand, it can inhibit the activity of aromatase, reduce the conversion of androgens to estrogens, thereby lowering the level of estrogen synthesis in the body and depriving tumor cells of the "nutrients" needed for growth. On the other hand, it can block the binding of estrogen to receptors, inhibit the estrogen receptor signaling pathway, interfere with the expression of genes related to tumor cell proliferation, differentiation, and survival, and reduce tumor cell proliferation.

In clinical application, it is mainly used for adjuvant treatment of postmenopausal hormone receptor positive breast cancer. Numerous studies have shown that the use of this drug can reduce the risk of recurrence in patients by approximately 30%. Compared with other anti breast cancer drugs, it has the convenience of oral preparation, and patients do not need to inject frequently, which improves the treatment compliance. Meanwhile, it has a lower risk of thrombosis, especially suitable for patients with concomitant cardiovascular diseases, reducing the occurrence of complications during treatment.

Endometriosis refers to the presence of endometrial tissue (glands and stroma) outside the uterine body, and is a common gynecological disease. Ectopic endometrial tissue can also be periodically affected by ovarian hormones, leading to proliferation, secretion, and shedding bleeding, resulting in a series of clinical symptoms. Acetate lanrelitide reduces estrogen levels in the body by inhibiting the secretion of ovarian estrogen. The decrease in estrogen levels can cause ectopic endometrial tissue to lose hormone support and gradually shrink. With the atrophy of ectopic endometrial tissue, patients' symptoms such as dysmenorrhea, menstrual disorders, and infertility are relieved.

This drug is suitable for patients with mild to moderate endometriosis, and for patients with mild symptoms and small lesions, it can be treated alone with lanrelitide acetate. For patients with severe conditions or those who have undergone surgical treatment, it can be used as adjuvant therapy after surgery to reduce the recurrence of the disease. Research shows that after treatment, patients' pain scores can be reduced by 50% -70%, significantly improving their quality of life. Moreover, the inhibition of ovarian function is reversible, and after discontinuation, ovarian function can gradually recover without affecting the patient's fertility.

Gastrointestinal pancreatic neuroendocrine tumors are a heterogeneous group of tumors originating from endocrine cells in the gastrointestinal tract and pancreas, with the ability to secrete multiple bioactive substances. Late stage GEP NETs are often unresectable or have already metastasized, making treatment difficult. It is a first-line therapeutic drug for advanced GEP NETs, with a multi-target mechanism of action. On the one hand, it can activate SSTR2/SSTR5 on the surface of tumor cells, directly inhibit tumor cell proliferation through a series of signaling pathways, and induce tumor cell apoptosis, controlling tumor growth at the cellular level. On the other hand, it can reduce the secretion of vascular endothelial growth factor (VEGF) and inhibit tumor angiogenesis.

The growth and metastasis of tumors rely on neovascularization to provide nutrients and oxygen. Inhibiting angiogenesis can effectively cut off the "nutrient supply" of tumors, limiting their growth and spread. Clinical studies have shown that after treatment, the progression free survival (PFS) of patients can be extended to 16-22 months, with an objective response rate (ORR) of 30% -40%. In addition, patients with GEP NETs often suffer from carcinoid syndrome, characterized by symptoms such as diarrhea and flushing, which seriously affect their quality of life. It can significantly alleviate these symptoms, reduce the frequency of use of short acting somatostatin analogs, and improve the comfort of patients' lives.

Pheochromocytoma and paraganglioma are a type of neuroendocrine tumor originating from the adrenal medulla or sympathetic ganglia, capable of synthesizing and secreting large amounts of catecholamines (such as adrenaline and norepinephrine). Excessive secretion of catecholamines can lead to symptoms such as hypertensive crisis, headache, and palpitations in patients, which can be life-threatening in severe cases. By inhibiting the synthesis and release of catecholamines, the level of catecholamines in the body can be effectively reduced. During the preoperative preparation stage, the use can control the patient's blood pressure and heart rate, reduce surgical risks, and improve surgical safety.

For patients who cannot undergo surgery, it can be used as a long-term medication to control the condition and continuously and stably inhibit the secretion of catecholamines. Research has shown that after treatment, patients' blood pressure fluctuations can be reduced by 40% -60%, significantly reducing the occurrence of catecholamine related complications such as arrhythmia and myocardial infarction, and improving patients' quality of life and survival.

Thyroid medullary carcinoma is a neuroendocrine tumor originating from the parafollicular cells (C cells) of the thyroid gland, with unique biological behavior and clinical manifestations. C cells can secrete calcitonin, and an increase in calcitonin levels is one of the important diagnostic indicators for medullary thyroid cancer. By inhibiting the secretion of calcitonin, it can serve as an indicator for monitoring disease changes and evaluating treatment efficacy.

At the same time, it can directly inhibit the proliferation of tumor cells and delay the progression of the disease. For patients with progressive or metastatic medullary thyroid cancer, especially those who are intolerant to targeted therapy, an effective treatment option is provided. Clinical data shows that after treatment with ranitidine acetate, patients' calcitonin levels can be reduced by 30% -50%, and some patients' tumor volume can be reduced, improving their symptoms and quality of life.

Tumor related pain is one of the common symptoms in cancer patients, which seriously affects their quality of life and psychological state. The pain mechanism caused by tumors is complex, with bone metastasis and nerve infiltration being common causes. During bone metastasis, tumor cells destroy bone tissue, release various pain mediators, activate nociceptors, and lead to the transmission of pain signals. Neuroinfiltration refers to the direct invasion of tumor cells into nerve tissue, causing neurological dysfunction and pain. By blocking the activation of nociceptors mediated by substance P, the transmission of pain signals is reduced.

At the same time, it can inhibit the transcription of c-fos mRNA, interfere with the transmission and integration of pain signals at the spinal cord level, thereby reducing pain caused by bone metastasis or nerve infiltration. For patients with poor efficacy or intolerance to traditional opioid drugs, ranitidine acetate provides a new treatment option. Research has shown that after treatment with lanrelitide acetate, patients' pain scores can be reduced by 30% to 50%, and the use of opioid drugs can be reduced by about 40%, reducing the risk of opioid related adverse reactions such as constipation and respiratory depression, and improving patients' quality of life.

Neuropathic pain is pain caused by nervous system injury or disease. Common causes include diabetes peripheral neuropathy, post herpetic neuralgia, etc. Its pain characteristics are spontaneous pain, hyperalgesia, and hyperalgesia, making treatment difficult. Acetate lanrelitide exerts analgesic effects by regulating the balance of neurotransmitters in the central nervous system.

It can increase the secretion of gamma aminobutyric acid (GABA), an important inhibitory neurotransmitter that can suppress neuronal excitability and reduce the transmission of pain signals. In clinical applications, as an adjuvant therapy for refractory neuropathic pain, it can significantly improve patients' pain symptoms and enhance their quality of life. Compared with other analgesics, it has relatively fewer adverse reactions and higher safety, providing a more effective treatment option for patients with neuropathic pain.